Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir
Loading...
Date
2020
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Hindawi Limited
Series Info
Canadian Journal of Gastroenterology and Hepatology;Volume 2020, 2020, Article number 1632959
Scientific Journal Rankings
Abstract
Background. Direct-acting antivirals (DAAs) made a drastic change in the management of HCV infection. Sofosbuvir is one of the highly potent DAAs, eliminated mainly through the kidney. But concerns about renal safety during treatment may limit its use. Neutrophil gelatinase-associated lipocalin (NGAL) has been proven as a predictor of renal tubular injury. Hence, the aim of this work was to assess serum neutrophil gelatinase-associated lipocalin (NGAL) in HCV-positive patients before and after treatment with the sofosbuvir-based antiviral regimen. Methods. This prospective study included 87 Egyptian patients with chronic HCV infection treated with sofosbuvir plus daclatasvir with or without ribavirin for 12 weeks. Serum NGAL was measured before and at the end of treatment (EOT). Analysis of NGAL and estimated glomerular filtration rate (eGFR) evolution was done. Results. Our results showed a statistically significant decrease in serum NGAL (P=0.02) with a nonsignificant reduction in eGFR (P=0.06). Moreover, changes in serum NGAL levels (baseline compared to EOT) in patients ranked by KDIGO-CKD classification showed a significant decrease in stages 1 and 2 (P=0.14 and 0.034, respectively) and a nonsignificant decrease in stage 3 (P=0.25). Also, eGFR changes after treatment in patients ranked by the same classifications showed a nonsignificant reduction in all stages (P>0.05). Conclusions. Sofosbuvir appears to have no nephrotoxic effects and is safe to treat patients with chronic HCV infection. © 2020 Ali Nada et al.
Description
MSA Google Scholar
SCOPUS
SCOPUS
Keywords
university of Sofosbuvi, Egyptian Patients, HCV-Positive, Lipocalin (NGAL), Serum Neutrophil
Citation
Blach, S., Zeuzem, S., Manns, M., Altraif, I., Duberg, A.-S., Muljono, D.H., Waked, I., (...), Razavi, H. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study (Open Access) (2017) The Lancet Gastroenterology and Hepatology, 2 (3), pp. 161-176. Cited 621 times. http://www.journals.elsevier.com/the-lancet-gastroenterology-and-hepatology doi: 10.1016/S2468-1253(16)30181-9 View at Publisher 2 Elghitany, I. Hepatitis C virus infection in Egypt: Current situation and future perspective (2019) Journal of High Institute of Public Health, 49 (1), pp. 1-9. 3 Etik, D.O., Ocal, S., Boyacioglu, A.S. Hepatitis C infection in hemodialysis patients: A review (Open Access) (2015) World Journal of Hepatology, 7 (6), pp. 885-895. Cited 28 times. http://www.wjgnet.com/1948-5182/pdf/v7/i6/885.pdf doi: 10.4254/wjh.v7.i6.885 View at Publisher 4 Kouyoumjian, S.P., Chemaitelly, H., Abu-Raddad, L.J. Characterizing hepatitis C virus epidemiology in Egypt: Systematic reviews, meta-analyses, and meta-regressions (Open Access) (2018) Scientific Reports, 8 (1), art. no. 1661. Cited 36 times. www.nature.com/srep/index.html doi: 10.1038/s41598-017-17936-4 View at Publisher 5 Strazzulla, A., Coppolino, G., Barreca, G.S., Gentile, I., Rivoli, L., Postorino, M.C., Mazzitelli, M., (...), Torti, C. Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals (Open Access) (2018) Clinical and Molecular Hepatology, 24 (2), pp. 151-162. Cited 3 times. https://www.e-cmh.org/journal/view.php?number=1408 doi: 10.3350/cmh.2017.0059 View at Publisher 6 Food And Drug Administration, T. (2013) FDA Approves Sovaldi for Chronic Hepatitis C. Cited 11 times. Baltimore, MD, USA The Food and Drug Administration 7 Lim, T.S., Ahn, S.H. Use of sofosbuvir in chronic kidney disease: Is it necessary? (Open Access) (2017) Clinical and molecular hepatology, 23 (4), pp. 308-310. Cited 3 times. doi: 10.3350/cmh.2017.0109 View at Publisher 8 Pawlotsky, J.M., Aghemo, A., Dusheiko, G., Forns, X., Puoti, M., Sarrazin, C. EASL recommendations on treatment of hepatitis C 2014 (2014) Journal of Hepatology, 61 (2), pp. 373-395. Cited 157 times. http://www.sciencedirect.com/science/journal/01688278 doi: 10.1016/j.jhep.2014.05.001 View at Publisher 9 Davenport, A., Cholongitas, E., Xirouchakis, E., Burroughs, A.K. Pitfalls in assessing renal function in patients with cirrhosis-potential inequity for access to treatment of hepatorenal failure and liver transplantation (Open Access) (2011) Nephrology Dialysis Transplantation, 26 (9), pp. 2735-2742. Cited 46 times. doi: 10.1093/ndt/gfr354 View at Publisher 10 Levin, A., Stevens, P.E., Bilous, R.W., Coresh, J., De Francisco, A.L.M., De Jong, P.E., Griffith, K.E., (...), Winearls, C.G. Kidney disease: Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease (Open Access) (2013) Kidney International Supplements, 3 (1), pp. 1-150. Cited 655 times. https://www.journals.elsevier.com/kidney-international-supplements doi: 10.1038/kisup.2012.73 View at Publisher 11 Singer, E., Schrezenmeier, E.V., Elger, A., Seelow, E.R., Krannich, A., Luft, F.C., Schmidt-Ott, K.M. Urinary NGAL-Positive Acute Kidney Injury and Poor Long-term Outcomes in Hospitalized Patients (Open Access) (2016) Kidney International Reports, 1 (3), pp. 114-124. Cited 8 times. http://www.journals.elsevier.com/kidney-international-reports doi: 10.1016/j.ekir.2016.07.003 View at Publisher 12 Vallet-Pichard, A., Mallet, V., Nalpas, B., Verkarre, V., Nalpas, A., Dhalluin-Venier, V., Fontaine, H., (...), Pol, S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest (2007) Hepatology, 46 (1), pp. 32-36. Cited 828 times. doi: 10.1002/hep.21669 View at Publisher 13 Lin, Z.-H., Xin, Y.-N., Dong, Q.-J., Wang, Q., Jiang, X.-J., Zhan, S.-H., Sun, Y., (...), Xuan, S.-Y. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: An updated meta-analysis (2011) Hepatology, 53 (3), pp. 726-736. Cited 430 times. doi: 10.1002/hep.24105 View at Publisher 14 Perico, N., Cattaneo, D., Bikbov, B., Remuzzi, G. Hepatitis C infection and chronic renal diseases (Open Access) (2009) Clinical Journal of the American Society of Nephrology, 4 (1), pp. 207-220. Cited 139 times. http://cjasn.asnjournals.org/cgi/reprint/4/1/207 doi: 10.2215/CJN.03710708 View at Publisher 15 Roche, B., Coilly, A., Duclos-Vallee, J.C., Samuel, D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC (Open Access) (2018) Liver International, 38, pp. 139-145. Cited 31 times. http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1478-3231 doi: 10.1111/liv.13659 View at Publisher 16 Garimella, T., Wang, R., Luo, W.-L., Hwang, C., Sherman, D., Kandoussi, H., Marbury, T.C., (...), Bifano, M. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment (2015) Antiviral Therapy, 20 (5), pp. 535-543. Cited 34 times. http://www.intmedpress.com/serveFile.cfm?sUID=6d3d8b78-48f2-4997-9f3c-f70be73ba5e8 doi: 10.3851/IMP2941 View at Publisher 17 Carrier, P., Essig, M., Debette-Gratien, M., Sautereau, D., Rousseau, A., Marquet, P., Jacques, J., (...), Loustaud-Ratti, V. Anti-hepatitis C virus drugs and kidney (Open Access) (2016) World Journal of Hepatology, 8 (32), pp. 1343-1353. Cited 12 times. http://www.wjgnet.com/esps/DownLoadFile.aspx?Type=Digital&SubType=1&DOI=10.4254%2fwjh.v8.i32.1343&FilePath=Pub%5c10.4254%5cv8%5ci32%5cWJH-8-1343.pdf doi: 10.4254/wjh.v8.i32.1343 View at Publisher 18 Xue, Y., Zhang, L.-X., Wang, L., Li, T., Qu, Y.-D., Liu, F. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection (Open Access) (2017) World Journal of Gastroenterology, 23 (32), pp. 5969-5976. Cited 8 times. https://www.wjgnet.com/1007-9327/journal/v23/i32/index.htm14 doi: 10.3748/wjg.v23.i32.5969 View at Publisher 19 Sansonno, D., Lauletta, G., Montrone, M., Grandaliano, G., Schena, F.P., Dammacco, F. Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection (2005) Clinical and Experimental Immunology, 140 (3), pp. 498-506. Cited 62 times. doi: 10.1111/j.1365-2249.2005.02778.x View at Publisher 20 Barsoum, R.S., William, E.A., Khalil, S.S. Hepatitis C and kidney disease: A narrative review (Open Access) (2017) Journal of Advanced Research, 8 (2), pp. 113-130. Cited 15 times. http://www.elsevier.com/wps/find/journaldescription.cws_home/722881/description#description doi: 10.1016/j.jare.2016.07.004 View at Publisher 21 Strazzulla, A., Coppolino, G., Di Fatta, C., Giancotti, F., D'Onofrio, G., Postorino, M.C., Mazzitelli, M., (...), Torti, C. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? (Open Access) (2016) World Journal of Hepatology, 8 (19), pp. 815-824. Cited 3 times. http://www.wjgnet.com/esps/DownLoadFile.aspx?Type=Digital&SubType=1&DOI=10.4254%2fwjh.v8.i19.815&FilePath=Pub%5c10.4254%5cv8%5ci19%5cWJH-8-815.pdf doi: 10.4254/wjh.v8.i19.815 View at Publisher 22 Bataille, S., Kaplanski, G., Boucraut, J., Halfon, P., Camus, C., Daniel, L., Burtey, S., (...), Dussol, B. Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits (2012) American Journal of Nephrology, 35 (2), pp. 134-140. Cited 11 times. doi: 10.1159/000335375 View at Publisher 23 Castillo, I., Martinez-Ara, J., Olea, T., Bartolomé, J., Madero, R., Hernández, E., Bernis, C., (...), Selgas, R. High prevalence of occult hepatitis C virus infection in patients with primary and secondary glomerular nephropathies (Open Access) (2014) Kidney International, 86 (3), pp. 619-624. Cited 18 times. https://www.journals.elsevier.com/kidney-international doi: 10.1038/ki.2014.68 View at Publisher 24 Gungor, G., Ataseven, H., Demir, A., Solak, Y., Gaipov, A., Biyik, M., Ozturk, B., (...), Polat, H. Neutrophil gelatinase-associated lipocalin in prediction of mortality in patients with hepatorenal syndrome: A prospective observational study (2014) Liver International, 34 (1), pp. 49-57. Cited 23 times. doi: 10.1111/liv.12232 View at Publisher 25 Alhaddad, O.M., Alsebaey, A., Amer, M.O., El-Said, H.H., Salman, T.A.H. Neutrophil Gelatinase-Associated Lipocalin: A New Marker of Renal Function in C-Related End Stage Liver Disease (Open Access) (2015) Gastroenterology Research and Practice, 2015, art. no. 815484. Cited 7 times. http://www.hindawi.com/journals/grp/ doi: 10.1155/2015/815484 View at Publisher 26 Gadde, S., Lee, B., Kidd, L., Zhang, R. Antineutrophil cytoplasmic antibodies crescentic allograft glomerulonephritis after sofosbuvir therapy (2016) World Journal of Nephrology, 5 (6), pp. 547-550. Cited 4 times. 27 Wanchoo, R., Thakkar, J., Schwartz, D., Jhaveri, K.D. Harvoni (Ledipasvir with Sofosbuvir)-Induced Renal Injury (2016) American Journal of Gastroenterology, 111 (1), pp. 148-149. Cited 22 times. http://www.nature.com/ajg/archive/index.html doi: 10.1038/ajg.2015.391 View at Publisher 28 Durand, F., Ni, L., De-Oertel, S. Safety of sofosbuvir-based regimens for the treatment of chronic HCV infection in patients with mild or moderate renal impairment (2016) Hepatology, 64-1 (867), p. 428A. Cited 3 times. 29 Telep, L., Brown, A., Brainard, D.M., Chokkalingam, A.P. Assessment of risk of acute kidney injury associated with exposure to sofosbuvir-containing HCV treatment regimens and HCV infection (2016) Hepatology, 64-1 (770), p. 380A. Cited 2 times. 30 Li, M., Chen, J., Fang, Z., Li, Y., Lin, Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: A systematic review and meta-analysis (Open Access) (2019) Virology Journal, 16 (1), art. no. 34. Cited 3 times. http://www.virologyj.com/home/ doi: 10.1186/s12985-019-1140-x View at Publisher